secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2026-09-03T20:18:54+00:00
Accession:  0001649094-26-000045
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte appoints CMO and CLO; narrows VAX-31 OPUS-1 topline data to end of October 2026
--------------------------------------------------------------------------------

- Luis Jodar, Ph.D., former Pfizer CMO for Vaccines and Infectious Diseases, joins as Chief Medical Officer.
- David McAvoy, J.D., former Teva Chief Legal Officer, joins as Chief Legal Officer; Mikhail Eydelman remains SVP, General Counsel.
- Topline safety, tolerability, and immunogenicity data from VAX-31 Phase 3 OPUS-1 trial now expected by end of October 2026, narrowing prior Q4 guidance.
- Jodar led clinical development and medical affairs for Prevnar 13 and Prevnar 20 at Pfizer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/0001649094-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/pcvx-20260831.htm
  HTML page:      https://secwatch.observer/filing/0001649094-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer